| Literature DB >> 33302922 |
Hirotaka Yonezawa1, Norio Yamamoto2, Katsuhiro Hayashi1, Akihiko Takeuchi1, Shinji Miwa1, Kentaro Igarashi1, Mickhael Bang Langit1,3, Hiroaki Kimura1, Shingo Shimozaki1, Takashi Kato1, Sei Morinaga1, Yoshihiro Araki1, Yohei Asano1, Hiroko Ikeda4, Takayuki Nojima1,4, Hiroyuki Tsuchiya1.
Abstract
BACKGROUND: Low-grade myofibroblastic sarcoma (LGMS) is described as a distinct atypical myofibroblastic tumor often with fibromatosis-like features and predilection for the head and neck, especially the oral cavity and larynx. LGMS arising in the levator scapulae muscle is extremely rare. CASEEntities:
Keywords: Infiltrative pattern; Intramuscular; Levator scapulae muscle; Low-grade myofibroblastic sarcoma; Wide excision
Mesh:
Year: 2020 PMID: 33302922 PMCID: PMC7731512 DOI: 10.1186/s12891-020-03857-3
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Clinical photographs of the patient. The tumor was located in the left levator scapulae muscle. a Front view. b Lateral view
Fig. 2Preoperative magnetic resonance images (MRI) of the tumor. MRI revealed a tumor in the levator scapulae muscle. The mass with a size of 2.5 × 3.5 cm was well-demarcated and myxomatous (arrow). a T1 weighted image (WI). b T2WI. c short TI inversion recovery (STIR). d Contrast-MRI revealed good enhancement with gadolinium
Fig. 3Clinical photograph of the surgery. The tumor was resected with a wide margin. a Intraoperative photograph showing the proximal side of the levator scapulae muscle was cut. b After wide excision. c Surgical specimen
Fig. 4Histological findings of the tumor. a On sectioning, a well-demarcated nodular tumor, measuring 3.2 × 2.3 × 2.0 cm, was observed. The tumor was a solid, firm, gray-white mass, without necrotic foci or hemorrhage. b Magnification × 10. c Magnification × 100. d Magnification × 400. Histologically, the tumor was composed of spindle cells arranged in fascicles or storiform growth pattern in fibrous stroma. Neoplastic cells have ill-defined cytoplasm and nuclei with atypia. A few mitoses were observed, and there was not hypercellular area or necrosis
Summary of the clinical features of previously reported 102 LGMS cases and the present case
| Authors | Case | Age | Sex | Size (cm) | Infiltrative pattern | EM | Treatment | FU (months) | LR | Oncological outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Mentzel et al. [ | 18 | 42 (19–72) | 11:7 | 4.0 (1.4–17) | Yes (12) No (6) | Yes (4) No (14) | E (10) WE (2) E + RT (2) E + CTX (1) E + CRT (1) N/A (2) | 35.9 (10–151) | Yes (3) No (8) N/A (7) | CDF (8) NED (2) AWD (1) N/A (7) |
| Montgomery et al. [ | 10 | 54.4 (28–73) | 8:2 | 4.7 (1.5–12) | Mostly | Yes (6) No (4) | E (6) WE (1) E + RT (1) WE+RT (1) N/A (1) | 48.1 (4–172) | Yes (4) No (5) N/A (1) | CDF (4) NED (2) N/A (4) |
| Meng et al. [ | 3 | 34 (14–74) | 3:0 | 4.2 (3–5) | Yes (3) | Yes (1) No (2) | E + RT (3) | 21.3 (16–27) | Yes (3) | NED (3) |
| Meng et al. [ | 14 | 30.5 (7–53) | 9:5 | 4.6 (2.0–15.0) | N/A (14) | Yes (1) No (13) | E (8) E + CTX (4) E + RT (2) | 28.3 (20–46) | Yes (5) No (8) N/A (1) | CDF (8) NED (5) N/A (1) |
| Cai et al. [ | 9 | 43.9 (6–73) | 6:3 | 2.7 (1.5–5.0) | N/A (9) | No (9) | Scraped (1) E (3) E + RT (1) WE + RT (3) Lobectomy (1) | 28.6 (11–44) | Yes (1) No (7) N/A (1) | CDF (7) NED (1) N/A (1) |
| Others [ | 48 | 43.8 (2–74) | 23:25 | 4.1 (0.4–22) | Yes (28) No (2) N/A (18) | Yes (10) No (38) | E (18) E + RT (1) WE (21) WE+CTX (2) WE+RT (2) CRT (1) Others (2) N/A (1) | 21.3 (6–72) | Yes (8) No (36) N/A (4) | CDF (36) NED (6) DOD (5) N/A (1) |
| Present case | 1 | 69 | female | 3.5 | Yes | No | WE | 96 | No | CDF |
LGMS Low-grade myofibroblastic sarcoma, M Male, F Female, N/A Not applicable, EM Electron microscopy, E Excision, WE Wide excision, CTX Chemotherapy, RT Radiotherapy, CRT Chemo-radiotherapy, LR Local recurrence, CDF Continuous disease free, NED No evidence of disease, AWD Alive with disease, DOD Death of disease
Comparisons of clinical features according to location of previously reported 102 LGMS cases and the present case
| Head and neck | Trunk | Extremity | Total | |
|---|---|---|---|---|
| Number of cases | 53 (51.5%) | 26 (25.2%) | 24 (23.3%) | 103 |
| Size (cm) | 2.7 cm (0.4–5.9) | 7.5 cm (1.2–22.0) | 4.9 cm (1.5–11.0) | 4.4 cm (0.4–22.0) |
| LGMS of soft tissue | 41/47 (87.2%) | 11/12 (91.6%) | 12/19 (63.3%) | 64/78 (82.0%) |
| SC (+D) | 7/47 (14.9%) | 4/12 (33.3%) | 4/19 (21.1%) | 15/78 (19.2%) |
| SM (+Mu) | 21/47 (44.7%) | 1/12 (8.4%) | 0/19 (0%) | 22/78 (28.2%) |
| IM | 11/47 (23.4%) | 2/12 (16.6%) | 4/19 (21.1%) | 17/78 (21.8%) |
| Others | 2/47 (4.2%) | 4/12 (33.3%) | 4/19 (21.1%) | 10/78 (12.8%) |
| LGMS of bone | 6/47 (12.8%) | 1/12 (8.4%) | 7/19 (36.7%) | 14/78 (18.0%) |
| Infiltrative pattern | ||||
| Yes | 28/29 (96.6%) | 10/14 (71.4%) | 6/9 (66.7%) | 44/52 (84.6%) |
| No | 1/29 (3.4%) | 4/14 (28.6%) | 3/9 (33.3%) | 8/52 (15.4%) |
LGMS Low-grade myofibroblastic sarcoma, D Dermis, SC Subcutaneous, Mu Mucosa, SM Submucosa, IM Intramuscular
Comparisons of oncological outcomes according to location of previously reported 102 LGMS cases and the present case
| Head and neck | Trunk | Extremity | Total | |
|---|---|---|---|---|
| Oncological outcome | ||||
| CDF | 35/48 (72.9%) | 15/23 (65.2%) | 14/18 (77.8%) | 64/89 (71.9%) |
| NED | 11/48 (22.9%) | 5/23 (21.7%) | 3/18 (16.7%) | 19/89 (21.4%) |
| AWD | 0/48 (0%) | 1/23 (4.4%) | 0/18 (0%) | 1/89 (1.1%) |
| DOD | 2/48 (4.2%) | 2/23 (8.7%) | 1/18 (5.5%) | 5/89 (5.6%) |
| Local recurrence | ||||
| Yes | 13/49 (26.5%) | 6/22 (27.3%) | 5/19 (26.3%) | 24/90 (26.7%) |
| No | 36/49 (73.5%) | 16/22 (72.7%) | 14/19 (73.7%) | 66/90 (73.3%) |
| Distant metastasis | ||||
| Yes | 1/49 (2.0%) | 2/23 (8.7%) | 1/19 (5.3%) | 4/91 (4.4%) |
| No | 48/49 (98.0%) | 21/23 (91.3%) | 18/19 (94.7%) | 87/91 (95.6%) |
LGMS Low-grade myofibroblastic sarcoma, CDF Continuous disease free, NED No evidence of disease, AWD Alive with disease, DOD Death of disease